Acamprosate Biomarker Stratification for Fragile X and Autism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fragile X Syndrome (FXS) and autism spectrum disorders (ASDs) lack effective therapies to address core social and communication impairments, with existing pharmacotherapies yielding uniformly negative results in large-scale trials, highlighting a need for new therapeutic approaches that can specifically target subgroups within these heterogeneous disorders.
Innovation Solution
The use of acamprosate, a compound that modulates serum levels of secreted amyloid precursor protein (sAPP) and brain-derived neurotrophic factor (BDNF) by administering it to patients and adjusting dosages based on plasma levels, as measured by specific antibodies, to achieve therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmacotherapies are used to treat FXS and ASD, then treatment coverage is provided, but treatment effectiveness is uniformly negative
Solution Approach 1:
The patent segments the heterogeneous ASD population into distinct subgroups based on biomarker profiles (sAPP, sAPPα, BDNF levels). This allows targeted pharmacotherapy where different compounds are administered to different subgroups, resolving the contradiction by making treatment effective for specific segments rather than uniformly failing across all patients
Solution Approach 2:
The patent measures and monitors biomarker parameters (sAPP, sAPPα, BDNF levels) to identify and track treatment response. By changing from non-specific clinical assessment to specific biomarker parameter monitoring, the patent enables both effective treatment selection and adaptation to individual patient responses
2Measurement precision
If large-scale trials are conducted to test pharmacotherapies, then statistical power is improved, but ability to identify appropriate subgroups is lost
Solution Approach 1:
The patent introduces biomarkers (sAPP, sAPPα, BDNF) as intermediary measures that bridge the gap between treatment administration and outcome assessment. These intermediaries provide precise measurement of treatment response while simultaneously serving as classifiers to identify appropriate subgroups, thus resolving the contradiction between measurement precision and subgroup identification
3Ease of operation
If heterogeneity of autism is addressed by treating all patients the same, then treatment simplicity is maintained, but treatment efficacy is reduced
Solution Approach 1:
The patent performs preliminary classification of patients into subgroups based on biomarker profiles before treatment initiation. This preliminary action enables tailored treatment selection that maintains operational simplicity (patients are clearly categorized) while significantly improving treatment efficacy through subgroup-specific pharmacotherapy
Data Source
Figure 1
Figure 2
AI summary
A method of treating and monitoring patient diagnosed with Autistic Spectrum disorder or Fragile X syndrome comprising measuring plasma biomarker levels of BDNF, sAPP, and sAPP alpha and adjusting the amount of a therapeutic compound according to the plasma levels of BDNF, sAPP and sAPPs. In one embodiment, the therapeutic compound is acamprosate.